Investor Panic Over Novo Nordisk 2026 Outlook

Novo Nordisk pre-released 2026 forecast, causing 18% stock drop in Copenhagen.
U.S. price cuts, patent expiries, and competition led to sales decline forecast.
1.5 million Americans use compounded GLP-1 drugs amid patent issues.
CEO warns 2026 sales may drop 5-13% due to market pressures.
Eli Lilly shares fell as investors fear competition from Novo Nordisk.
Wegovy prescriptions hit 50,000 weekly despite past growth gains.

Finance | Pharmaceuticals | Stocks

United States | Denmark

Mike Doustdar

3 weeks ago